Report Highlights

Affective Computing in the U.S.: Market Overview

The U.S. affective computing market was valued at USD 4.9 billion in 2024 and is forecast to reach USD 13.4 billion by 2032, growing at a CAGR of 13.4%. Revenue is split between software licences for facial expression and voice analysis, sensor hardware from vendors such as Smart Eye, and integration services sold to automotive OEMs and health systems. Private-sector firms, hyperscalers such as Microsoft, Amazon Web Services and IBM, and specialist start-ups have led product development.

Government has acted mainly as a constraint rather than a buyer. Federal funding reaches the field through National Science Foundation AI Research Institutes, but no federal programme procures affective computing at scale. State legislatures have set the commercial terms instead, most notably Illinois through the Biometric Information Privacy Act and Texas through its Capture or Use of Biometric Identifier Act. Private firms have therefore led product development, with consent tooling now a differentiator.

Policy-Driven Growth in U.S. Affective Computing

The Centers for Medicare and Medicaid Services created billing codes G0552 through G0554 in its 2025 Physician Fee Schedule for digital mental health treatment devices cleared under 21 CFR 882.5801. Clinicians can now bill for software that tracks patient emotional responses during therapy, converting one-off device sales into recurring reimbursed revenue. The CHIPS and Science Act of 2022 adds a supply mechanism, allocating USD 39 billion in Commerce Department manufacturing incentives that lower edge AI processor costs.

FDA's final guidance on Predetermined Change Control Plans for AI-enabled device software functions, issued in December 2024, lets manufacturers pre-authorise model updates without new 510(k) or De Novo submissions. Emotion-recognition models can therefore be retrained on new populations and redeployed in clinical software within an approved change envelope. This shortens product cycles and lets vendors compete on continuously improving accuracy. Clearance durability, rather than initial approval, becomes the commercial moat.

Regulatory Barriers and Compliance Costs

Illinois' Biometric Information Privacy Act (740 ILCS 14) is enforced through private litigation, with statutory damages of USD 1,000 per negligent violation and USD 5,000 per intentional or reckless violation. Each written release, retention schedule and public disclosure is a compliance cost borne before any model runs. Texas' Capture or Use of Biometric Identifier Act (Tex. Bus. & Com. Code Chapter 503) is enforced by the Texas Attorney General, with civil penalties of up to USD 25,000 per violation.

FDA's Center for Devices and Radiological Health reviews emotion-aware clinical software through 510(k) or De Novo pathways, with a typical total review period of roughly 150 to 200 days including sponsor responses. Colorado's Artificial Intelligence Act (SB 24-205) imposes duty-of-care obligations on deployers of high-risk AI, enforced by the Colorado Attorney General, with its effective date delayed to 30 June 2026. New York City Local Law 144 requires an independent bias audit for automated employment decision tools, administered by the Department of Consumer and Worker Protection.

Policy-Created Opportunities in U.S. Affective Computing

CMS billing codes G0552 through G0554 create a reimbursable channel for FDA-cleared devices under 21 CFR 882.5801, rewarding vendors that obtain clearance early. Mental health providers, digital therapeutics firms and telehealth platforms can embed emotion-responsive scoring into covered treatment sessions. Vendors that pair clearance with clinical outcome data gain an advantage over uncleared wellness applications that cannot bill.

Section 24220 of the Infrastructure Investment and Jobs Act directs NHTSA to mandate advanced impaired-driving prevention technology, creating demand for in-cabin driver-state sensing. Tier 1 suppliers that build camera and physiological monitoring into vehicle platforms, including Smart Eye's existing driver monitoring contracts with OEMs, are positioned to meet the mandate. OMB Memorandum M-24-10 also requires federal agencies to manage high-impact AI under NIST AI Risk Management Framework practices, opening a documentation services niche for government suppliers.

Market at a Glance

Leading Market Participants

• Smart Eye
• Affectiva
• Realeyes
• Cogito
• Hume AI
• Noldus Information Technology
• Microsoft
• IBM
• Amazon Web Services
• Beyond Verbal

Regulatory and Policy Environment

The U.S. has no single federal statute governing affective computing. The primary framework is state law: Illinois BIPA (740 ILCS 14), Texas CUBI (Chapter 503), and the California Consumer Privacy Act as amended by the California Privacy Rights Act. The California Privacy Protection Agency finalised automated decisionmaking technology regulations in 2025, with compliance obligations phasing in from 1 January 2027. The FTC polices unfair or deceptive biometric practices under Section 5 of the FTC Act.

Key compliance requirements cluster around written notice, informed consent before collection, published retention schedules and bias audits. Colorado's AI Act takes effect 30 June 2026, requiring impact assessments for high-risk systems used in consequential decisions such as employment and healthcare. Compared with the EU AI Act, which prohibits emotion recognition in workplaces and educational institutions from 2 February 2025, U.S. federal rules remain permissive, and state consent regimes set the constraints.

Long-Term Policy Outlook for U.S. Affective Computing

Federal preemption is the central uncertainty. Congress considered a moratorium on state AI legislation during 2025 budget reconciliation, and the Senate removed it by a 99–1 vote in July 2025. If Congress enacts a federal framework that preempts state law, the consent-based regimes of Illinois and Texas would give way to a single national standard. Until then, state legislatures will continue to shape market access.

By 2032, expect CMS to widen digital mental health treatment codes beyond behavioural therapy, extending reimbursement to emotion-responsive monitoring tools in chronic care. The FDA's change control framework will mature, enabling continuously updated affective models in clinical settings. Vendors that build consent architecture now will face lower retrofit costs than competitors forced to re-engineer data pipelines after state enforcement.